Table 2.
Clinical characteristics by study and combined, After Breast Cancer Pooling Projecta
| SBCSS (n=4,886) | WHEL (n=3,088) | LACE (n=2,265) | NHS
|
Combined (n=18,314) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All cases (n=8,075) | Cases diagnosed ≥ 1990 (n=5,115) | |||||||||||
| n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | n | (%) | |
| Age at diagnosis (years) | ||||||||||||
| Mean (SD) | 53.5 (10.0) | 51.2 (8.9) | 58.3 (11.0) | 60.4 (9.4) | 64.5 (7.8) | 56.6 (10.4) | ||||||
| TNM Stage (AJCC 6th edition)b | ||||||||||||
| I | 1,679 | (36.1) | 1,191 | (38.6) | 1,057 | (46.7) | 4,044 | (53.8) | 2,915 | (59.7) | 7,971 | (45.5) |
| II | 2,209 | (47.4) | 1,410 | (45.7) | 949 | (41.9) | 2,295 | (30.5) | 1,389 | (28.5) | 6,863 | (39.2) |
| III | 740 | (15.9) | 487 | (15.8) | 258 | (11.4) | 935 | (12.4) | 459 | (9.4) | 2,420 | (13.8) |
| IV | 28 | (0.6) | 0 | 0 | 248 | (3.3) | 119 | (2.4) | 276 | (1.6) | ||
| Missing | 230 | 0 | 1 | 553 | 233 | 784 | ||||||
| ER/PR status | ||||||||||||
| ER+/PR+ | 2,439 | (51.0) | 1,908 | (63.1) | 1,530 | (68.3) | 3,848 | (61.6) | 2,913 | (64.8) | 9,725 | (59.7) |
| ER+/PR− | 635 | (13.3) | 368 | (12.2) | 319 | (14.2) | 1,068 | (17.1) | 745 | (16.6) | 2,390 | (14.7) |
| ER−/PR+ | 362 | (7.6) | 129 | (4.3) | 41 | (1.8) | 219 | (3.5) | 132 | (2.9) | 751 | (4.6) |
| ER−/PR− | 1,350 | (28.2) | 618 | (20.4) | 350 | (15.6) | 1,112 | (17.8) | 705 | (15.7) | 3,430 | (21.1) |
| Missing | 100 | 65 | 25 | 1,828 | 620 | 2,018 | ||||||
| HER2 | ||||||||||||
| Positive | 837 | (30.5) | 180 | (8.3) | 320 | (16.3) | 161 | (12.9) | 161 | (13.0) | 1,498 | (18.5) |
| Negative | 1,689 | (61.4) | 1,775 | (82.2) | 1,643 | (83.6) | 967 | (77.7) | 965 | (77.7) | 6,074 | (74.8) |
| Indeterminate | 223 | (8.1) | 205 | (9.5) | 2 | (0.1) | 116 | (9.3) | 116 | (9.3) | 546 | (6.7) |
| Missing | 2,137 | 928 | 300 | 6,831 | 3,873 | 10,196 | ||||||
| Histological grade | ||||||||||||
| Well differentiated | 435 | (17.1) | 484 | (17.1) | 430 | (21.0) | 943 | (20.6) | 837 | (22.3) | 2,292 | (19.1) |
| Moderately | 943 | (46.0) | 1,954 | (42.7) | 1,675 | (44.5) | 5,441 | (45.3) | ||||
| differentiated | 1,304 | (51.2) | 1,240 | (43.8) | ||||||||
| Poorly differentiated | 806 | (31.7) | 1,108 | (39.1) | 679 | (33.1) | 1,682 | (36.7) | 1,250 | (33.2) | 4,275 | (35.6) |
| Missing | 2,341 | 256 | 213 | 3,496 | 1,353 | 6,306 | ||||||
| Surgery | ||||||||||||
| None | 9 | (0.2) | 1 | (0.03) | 0 | (0.0) | 92 | (1.4) | 40 | (0.9) | 102 | (0.6) |
| Lumpectomy | 45 | (0.9) | 1,474 | (47.7) | 1,146 | (50.6) | 2,835 | (43.8) | 2,476 | (52.8) | 5,500 | (32.9) |
| Mastectomy | 4,592 | (94.0) | 1,613 | (52.2) | 1,119 | (49.4) | 3,548 | (54.8) | 2,178 | (46.4) | 10,872 | (65.1) |
| Unknown type | 240 | (4.9) | 0 | 0 | 0 | 0 | 240 | (1.4) | ||||
| Missing | 0 | 0 | 0 | 1,600 | 421 | 1,600 | ||||||
| Chemotherapyc | ||||||||||||
| No | 382 | (7.8) | 927 | (30.0) | 967 | (42.7) | 3,308 | (58.5) | 2,722 | (60.9) | 5,584 | (35.1) |
| Yes | 4,504 | (92.2) | 2,159 | (70.0) | 1,297 | (57.3) | 2,350 | (41.5) | 1,748 | (39.1) | 10,310 | (64.9) |
| Missing | 0 | 2 | 1 | 2,417 | 645 | 2,420 | ||||||
| Radiotherapy | ||||||||||||
| No | 3,286 | (67.3) | 1,185 | (38.4) | 837 | (37.0) | 2,520 | (43.1) | 1,849 | (39.7) | 7,828 | (48.7) |
| Yes | 1,600 | (32.8) | 1,899 | (61.6) | 1,428 | (63.1) | 3,330 | (56.9) | 2,810 | (60.3) | 8,257 | (51.3) |
| Missing | 0 | 4 | 0 | 2,225 | 456 | 2,229 | ||||||
| Endocrine therapyc | ||||||||||||
| No | 2,315 | (47.5) | 978 | (31.7) | 451 | (20.1) | 2,374 | (36.7) | 1,270 | (27.1) | 6,118 | (36.7) |
| Yes | 2,555 | (52.5) | 2,106 | (68.3) | 1,793 | (79.9) | 4,102 | (63.3) | 3,422 | (72.9) | 10,556 | (63.3) |
| Missing | 16 | 4 | 21 | 1,599 | 423 | 1,640 | ||||||
SBCSS Shanghai Breast Cancer Survival Study, WHEL Women’s Healthy Eating and Living Study, LACE Life After Cancer Epidemiology Study, NHS Nurses’ Health Study
a
All percentages exclude missing data.
b
WHEL and LACE did not include women diagnosed with stage IIIB or IV breast cancer.
c
Based on one measure at baseline/first post-diagnosis survey.